Redmile Group LLC Has $2.51 Million Stock Holdings in Repare Therapeutics Inc. (NASDAQ:RPTX)

Redmile Group LLC lowered its stake in Repare Therapeutics Inc. (NASDAQ:RPTX) by 1.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 1,916,089 shares of the company’s stock after selling 26,466 shares during the period. Redmile Group LLC’s holdings in Repare Therapeutics were worth $2,510,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Barclays PLC grew its position in Repare Therapeutics by 1,471.7% during the 3rd quarter. Barclays PLC now owns 8,330 shares of the company’s stock worth $29,000 after acquiring an additional 7,800 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Repare Therapeutics by 204.7% during the fourth quarter. Tower Research Capital LLC TRC now owns 34,423 shares of the company’s stock worth $45,000 after purchasing an additional 23,127 shares during the last quarter. Vontobel Holding Ltd. grew its holdings in shares of Repare Therapeutics by 45.8% during the fourth quarter. Vontobel Holding Ltd. now owns 35,000 shares of the company’s stock worth $46,000 after purchasing an additional 11,000 shares during the last quarter. Lynx1 Capital Management LP acquired a new position in shares of Repare Therapeutics in the fourth quarter valued at approximately $104,000. Finally, JPMorgan Chase & Co. raised its holdings in Repare Therapeutics by 2,144,950.0% in the 4th quarter. JPMorgan Chase & Co. now owns 85,802 shares of the company’s stock valued at $112,000 after buying an additional 85,798 shares during the last quarter. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Price Performance

Shares of RPTX opened at $1.31 on Thursday. The business has a 50-day moving average of $1.16 and a 200-day moving average of $1.71. The company has a market capitalization of $55.97 million, a price-to-earnings ratio of -0.65 and a beta of 0.85. Repare Therapeutics Inc. has a 1 year low of $0.89 and a 1 year high of $4.29.

Repare Therapeutics (NASDAQ:RPTX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.10. Repare Therapeutics had a negative net margin of 99.76% and a negative return on equity of 40.87%. As a group, sell-side analysts anticipate that Repare Therapeutics Inc. will post -2.04 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright decreased their price target on shares of Repare Therapeutics from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Friday, March 7th.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.